Adcendo seeks to develop antibody-drug conjugates to create new medicines for cancer patients with a significant unmet need.
The company was founded in 2017 in Copenhagen, as a spin-out from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen.
The company was founded in 2017 in Copenhagen, as a spin-out from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen.
Location: Denmark, Capital Region of Denmark, Copenhagen
Employees: 11-50
Total raised: $436.66M
Founded date: 2017
Investors 3
| Date | Name | Website |
| - | RA Capital... | racap.com |
| 01.01.2025 | TCG Crosso... | tcgcrossov... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 6
| Date | Series | Amount | Investors |
| 14.04.2026 | - | $75M | - |
| 25.11.2024 | Series B | $135M | - |
| 29.05.2024 | Series A | $17.3M | - |
| 04.04.2023 | Series A | $89.55M | - |
| 12.01.2022 | Series A | $57.95M | - |
| 29.04.2021 | Series A | $61.86M | Novo Holdi... |
Mentions in press and media 22
| Date | Title | Description |
| 28.08.2026 | China's DualityBio Rises After Forging USD1 Billion Cancer Drug Tie-Up With Roche Unit | (Yicai) Aug. 28 -- Shares of Duality Biotherapeutics rose after it said it has agreed to co‑develop next‑generation antibody‑drug conjugates for multiple oncology indications with Genentech, a subsidiary of Switzerland's Roche, based on the... |
| 14.04.2026 | Adcendo Raises $75M to Advance Cancer Drug Pipeline | Adcendo, a clinical-stage biotech from Copenhagen, announced it has raised $75M of Series C funding to accelerate the clinical development of its pioneering cancer medicines. The financing was led by Jeito Capital with participation from ne... |
| 24.03.2026 | DualityBio (9606.HK) Announces 2025 Annual Results | HONG KONG, March 24, 2026 /PRNewswire/ -- Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as "DualityBio" or the "Company"), a leading global clinical-stage innovative biop... |
| 19.10.2025 | Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced... | AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in... |
| 25.11.2024 | Adcendo Closes $135M Series B Financing | Adcendo, a Copenhagen, Denmark-based biotech company focused on the development of ADCs for the treatment of cancers with a high unmet medical need, raised $135M in Series B funding. The round was led by TCGX, with participation from new in... |
| 25.11.2024 | Novo Holdings-backed Adcendo secures $135M for ADC pipeline | Adcendo is adding $135 million to its arsenal, money that will go toward launching several antibody-drug conjugate (ADC) candidates into the clinic. California-based investor TCGX led the oversubscribed series B financing, with new investor... |
| 29.05.2024 | Adcendo Raises €16M; Extends Series A to €98M | Adcendo, a Copenhagen, Denmark-based biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers, raised additional €16M in additional Series A extension funding. The round, which ... |
| 14.04.2023 | Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting | Copenhagen, Denmark, 13 April, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, will be presenting nove... |
| 04.04.2023 | Adcendo ApS Announces Extension of Series A financing to 82M EUR toEnsure Broad Development of its First-in-class ADC Pipeline | Copenhagen, Denmark, April 4th, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the su... |
| 04.04.2023 | Over DKK 3 billion (USD 413 million) raised by BioInnovation Institute portfolio companies to date | Portfolio company Adcendo Aps, today announces extension of Series A financing to 82M EUR. BII publishes its 2022 Impact Report outlining the success of its portfolio companies in the past year. BII's ambition is to support early-stage life... |
Show more